Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Xilio Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 34
- +3 vs. Q3 2023
- Shares held
- 16.4M
- +566.2K (+3.6%) vs. Q3 2023
- Total value
- $9.03M
- −$24.4M (−73.0%) vs. Q3 2023
- New holders
- 6
- 8 more added
- Sold out
- 3
- 4 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 468 | $0 | 0.00% | +118+33.7% | Added |
| Qube Research & Technologies Ltd | 4 | $2 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 11 | $6 | 0.00% | −226,708−100.0% | Reduced |
| Cullen/Frost Bankers, Inc. | 100 | $55 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 106 | $58 | 0.00% | +6+6.0% | Added |
| UBS Group AG | 201 | $111 | 0.00% | 00.0% | Unchanged |
| Key Financial Inc | 830 | $456 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 2,857 | $1.57K | 0.00% | +135+5.0% | Added |
| Dunhill Financial, LLC | 10,274 | $5.65K | 0.01% | +10,274 | New |
| Virtu Financial LLC | 10,763 | $6.00K | 0.00% | +10,763 | New |
| Charles Schwab Investment Management Inc | 11,925 | $6.56K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 13,975 | $7.69K | 0.00% | +10,093+260.0% | Added |
| State Street Corp | 15,690 | $8.63K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 17,798 | $9.79K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 30,351 | $16.7K | 0.00% | +30,351 | New |
| BlackRock Inc. | 46,862 | $25.8K | 0.00% | −522−1.1% | Reduced |
| Citadel Advisors LLC | 51,419 | $28.3K | 0.00% | +51,419 | New |
| ArrowMark Colorado Holdings LLC | 83,373 | $45.9K | 0.00% | +83,373 | New |
| Geode Capital Management, LLC | 84,826 | $46.7K | 0.00% | 00.0% | Unchanged |
| Laurion Capital Management LP | 116,847 | $64.3K | 0.00% | −22,413−16.1% | Reduced |
| Morgan Stanley | 127,265 | $70.0K | 0.00% | +101,000+384.5% | Added |
| Bridgeway Capital Management, LLC | 155,481 | $85.5K | 0.00% | +45,000+40.7% | Added |
| Renaissance Technologies LLC | 209,700 | $115.0K | 0.00% | +189,000+913.0% | Added |
| FIL Ltd | 218,705 | $120.3K | 0.00% | 00.0% | Unchanged |
| Trustees of Columbia University in the City of New York | 249,635 | $137.3K | 0.29% | 00.0% | Unchanged |
| Artal Group S.A. | 450,000 | $248.0K | 0.01% | 00.0% | Unchanged |
| Vanguard Group Inc | 902,531 | $496.4K | 0.00% | +12,178+1.4% | Added |
| Rock Springs Capital Management LP | 1,440,759 | $792.4K | 0.02% | 00.0% | Unchanged |
| RiverVest Venture Management LLC | 1,441,444 | $792.8K | 2.92% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $811.3K | 0.25% | +1,475,121 | New |
| Octagon Capital Advisors LP | 1,785,000 | $981.8K | 0.16% | −533,500−23.0% | Reduced |
| FMR LLC | 1,907,671 | $1.05M | 0.00% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $1.52M | 0.18% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $1.54M | 0.15% | 00.0% | Unchanged |
| Harvard Management Co Inc | 0 | $0 | 0.00% | −416,059−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −226,941−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −26,449−100.0% | Sold out |